The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B: A multicenter study conducted in a real clinical setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon J.H. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Kim S.G. | - |
dc.contributor.author | Jang J.W. | - |
dc.contributor.author | Kim T.H. | - |
dc.contributor.author | Jung Y.K. | - |
dc.contributor.author | Kwon O.S. | - |
dc.date.available | 2020-11-02T22:43:32Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/11355 | - |
dc.description.abstract | Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B: A multicenter study conducted in a real clinical setting | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5009/gnl.2013.7.2.197 | - |
dc.identifier.scopusid | 2-s2.0-84875113234 | - |
dc.identifier.bibliographicCitation | Gut and Liver, v.7, no.2, pp 197 - 205 | - |
dc.citation.title | Gut and Liver | - |
dc.citation.volume | 7 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 197 | - |
dc.citation.endPage | 205 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.subject.keywordPlus | hepatitis E antigen | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | virus DNA | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | chronic hepatitis | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | depression | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug eruption | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | edema | - |
dc.subject.keywordPlus | epigastric pain | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | flu like syndrome | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | hair loss | - |
dc.subject.keywordPlus | hepatitis B | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | insomnia | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | leukopenia | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | seroconversion | - |
dc.subject.keywordPlus | treatment refusal | - |
dc.subject.keywordPlus | university hospital | - |
dc.subject.keywordPlus | virology | - |
dc.subject.keywordPlus | weakness | - |
dc.subject.keywordAuthor | Asian continental ancestry group | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Peginterferon | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.